Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

UNIVERSITY OF WASHINGTON

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1861-01-01

Employees: 10K

Market Cap: -

Website: https://www.cs.washington.edu

Clinical Trials

Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer

Not Applicable

Completed

Conditions: Male Breast Cancer
Nausea and Vomiting
Stage IIIA Breast Cancer
Stage I Breast Cancer
Stage II Breast Cancer

Interventions: Drug: palonosetron hydrochloride
Drug: cyclophosphamide
Drug: dexamethasone
Drug: doxorubicin hydrochloride
Procedure: quality-of-life assessment
Procedure: nausea and vomiting therapy
Procedure: management of therapy complications
Drug: ondansetron hydrochloride
Other: survey administration

First Posted Date: 2006-06-23

Last Posted Date: 2017-07-11

Lead Sponsor: University of Washington

Target Recruit Count: 41

Registration Number: NCT00343863

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer

Phase 2

Completed

Conditions: Stage IIIB Breast Cancer
Male Breast Cancer
HER2-positive Breast Cancer
Stage IV Breast Cancer
Stage IIIC Breast Cancer

Interventions: Biological: HER-2/neu intracellular domain protein
Procedure: leukapheresis
Other: laboratory biomarker analysis
Biological: sargramostim
Other: immunologic technique
Biological: synthetic tumor-associated peptide vaccine therapy

First Posted Date: 2006-06-22

Last Posted Date: 2020-02-12

Lead Sponsor: University of Washington

Target Recruit Count: 38

Registration Number: NCT00343109

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Promoting Infant Mental Health in Foster Care

Phase 2

Completed

Conditions: Child Development
Child Behavior Disorders
Reactive Attachment Disorder

Interventions: Behavioral: Promoting First Relationships Program
Behavioral: Early Education Support Program

First Posted Date: 2006-06-21

Last Posted Date: 2012-05-17

Lead Sponsor: University of Washington

Target Recruit Count: 236

Registration Number: NCT00339365

Locations: 🇺🇸
University of Washington, Seattle, Washington, United States

Evaluating the Safety of G-CSF Mobilization in Individuals With Beta Thalassemia Major

Not Applicable

Completed

Conditions: Beta-Thalassemia

Interventions: Drug: Hydroxyurea

First Posted Date: 2006-06-13

Last Posted Date: 2012-12-20

Lead Sponsor: University of Washington

Target Recruit Count: 26

Registration Number: NCT00336362

Locations: 🇬🇷
George Papanicolaou Hospital, Thessaloniki, Greece

Doxorubicin Hydrochloride Liposome, Cyclophosphamide, and Trastuzumab in Treating Patients With Stage IV Breast Cancer

Phase 1

Completed

Conditions: Male Breast Cancer
HER2-positive Breast Cancer
Stage IV Breast Cancer
Recurrent Breast Cancer

Interventions: Drug: pegylated liposomal doxorubicin hydrochloride
Drug: cyclophosphamide
Biological: trastuzumab

First Posted Date: 2006-05-31

Last Posted Date: 2017-07-26

Lead Sponsor: University of Washington

Target Recruit Count: 30

Registration Number: NCT00331552

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Pilot Community Clinical Study of Hypothermia in Cardiac Arrest

Phase 1

Completed

Conditions: Cardiac Arrest

Interventions: Drug: Up to 2 liter infusion of cold 4 degree C normal saline

First Posted Date: 2006-05-24

Last Posted Date: 2017-04-17

Lead Sponsor: University of Washington

Target Recruit Count: 125

Registration Number: NCT00329563

Vancomycin Or Trimethoprim/Sulfamethoxazole for Methicillin-resistant Staphylococcus Aureus Osteomyelitis

Phase 3

Completed

Conditions: Osteomyelitis
Methicillin-resistant Staphylococcus Aureus

Interventions: Drug: trimethoprim-sulfamethoxazole
Drug: vancomycin

First Posted Date: 2006-05-11

Last Posted Date: 2023-04-11

Lead Sponsor: University of Washington

Target Recruit Count: 2

Registration Number: NCT00324922

Locations: 🇺🇸
University of Washington, Seattle, Washington, United States

Hypertonic Resuscitation Following Traumatic Injury

Phase 3

Terminated

Conditions: Shock, Traumatic

Interventions: Drug: 7.5% hypertonic saline/6% Dextran-70 (HSD)
Drug: 7.5% hypertonic saline (HS)
Drug: 0.9% normal saline

First Posted Date: 2006-04-19

Last Posted Date: 2011-03-01

Lead Sponsor: University of Washington

Target Recruit Count: 895

Registration Number: NCT00316017

Locations: 🇺🇸
Alabama Resuscitaion Center, University of Alabama, Birmingham, Alabama, United States
🇺🇸
UCSD-San Diego Resuscitation Research Center, San Diego, California, United States
🇺🇸
Iowa Resuscitation Network, University of Iowa Carver College of Medicine, Iowa City, Iowa, United States

and more 7 locations

Hypertonic Resuscitation Following Severe Traumatic Brain Injury (TBI)

Phase 3

Terminated

Conditions: Brain Injuries, Traumatic

Interventions: Drug: 7.5% Hypertonic Saline in 6% Dextran-70 (HSD)
Drug: 7.5% Hypertonic Saline (HS)
Drug: 0.9% Normal Saline (NS)

First Posted Date: 2006-04-19

Last Posted Date: 2011-05-19

Lead Sponsor: University of Washington

Target Recruit Count: 1331

Registration Number: NCT00316004

Locations: 🇺🇸
Alabama Resuscitation Center, University of Alabama, Birmingham, Alabama, United States
🇺🇸
Orange County/UC Irvine, Orange, California, United States
🇺🇸
UCSD-San Diego Resuscitation Research Center, San Diego, California, United States

and more 9 locations

Intravaginal LACTIN-V for Prevention of Recurrent Urinary Tract Infection

Phase 2

Completed

Conditions: Urinary Tract Infection

Interventions: Drug: Placebo
Drug: Lactin-V

First Posted Date: 2006-03-21

Last Posted Date: 2023-04-14

Lead Sponsor: University of Washington

Target Recruit Count: 100

Registration Number: NCT00305227

Locations: 🇺🇸
Hall Health Primary Care Center, University of Washington, Seattle, Washington, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy